In Plain English: The Clinical Takeaway
- Better Glucose Stability: Weekly GLP-1 medications help smooth out blood sugar curves, keeping glucose levels within the target range for longer periods during the day.
- Reduced Insulin Need: Patients require fewer daily units of insulin because these drugs slow stomach emptying and curb the hormone glucagon, which normally raises blood sugar.
- Weight Management Benefits: Clinical trials demonstrate meaningful weight loss and reduced carbohydrate intake without raising the risk of severe low blood sugar episodes.
Understanding the Mechanism of Action in Type 1 Diabetes
GLP-1 receptor agonists were originally developed to treat type 2 diabetes and obesity by mimicking a natural gut hormone released after eating. By slowing gastric emptying, these compounds ensure that dietary glucose enters the bloodstream much more gradually. Simultaneously, they suppress the release of glucagon, a hormone that typically signals the liver to release stored glucose.
According to clinical analyses, these combined pathways blunt the sharp post-meal glucose spikes that are difficult for conventional insulin therapy to catch. Because continuous glucose monitor (CGM) data consistently reflects flatter glucose curves, researchers have expanded investigations into how these weekly injectables integrate with modern diabetes technology. Off-label prescribing has risen sharply as clinicians observe these metabolic advantages in real-world settings.
Earlier clinical investigations, such as the ADJUNCT ONE and ADJUNCT TWO studies evaluating older agents like liraglutide and exenatide, confirmed modest hemoglobin A1c reductions of 0.1–0.7%, meaningful weight loss, and lower insulin requirements. However, those early trials also flagged initial concerns regarding hypoglycemia and ketosis that tempered enthusiasm for years. Newer generation randomized controlled trials have since provided a clearer picture of how modern formulations perform.
A randomized crossover trial published in Nature Medicine (Pasqua et al.) evaluated weekly semaglutide combined with automated insulin delivery in adults with type 1 diabetes. The data demonstrated that participant time in range improved from 69.4% to 74.2%, while daily insulin requirements dropped by an average of 11.3 units. Participants also decreased their overall body weight and carbohydrate intake without experiencing an uptick in hypoglycemia. A separate trial published in NEJM Evidence (Shah et al.) reported that roughly one in three participants with type 1 diabetes and obesity achieved a combined clinical goal of improved time-in-range, low hypoglycemia, and at least 5% weight loss.
| Trial / Study Group | Intervention Drug | Key Efficacy Findings | Safety Observations |
|---|---|---|---|
| Pasqua et al. (Nature Medicine, 2025) | Weekly Semaglutide + AID | Time in range improved to 74.2%; daily insulin reduced by 11.3 units. | No increase in hypoglycemia; weight loss observed. |
| Shah et al. (NEJM Evidence, 2025) | Semaglutide in T1D with Obesity | One in three patients met combined goals of glycemic control and 5% weight loss. | Favorable profile with low hypoglycemia rates. |
| Observational Phase 2 Data | Tirzepatide (Dual GIP/GLP-1) | Weight loss of 10–20 kg; insulin dose reductions exceeding 30%. | Improved CGM time in range. |
Cardiovascular and Renal Implications
Beyond glycemic variability, patients managing type 1 diabetes face elevated risks of cardiovascular disease and kidney disease over time. In populations with type 2 diabetes and obesity, GLP-1 receptor agonists have shown powerful protective effects in those areas. Researchers have increasingly turned their attention toward whether these systemic benefits translate effectively to the type 1 diabetes community.
Unlike SGLT2 inhibitors, which have faced concerns over diabetic ketoacidosis (DKA) in type 1 diabetes patients, clinical trials involving GLP-1 receptor agonists have not reported an increase in DKA. Because GLP-1 drugs do not suppress insulin secretion or alter ketone metabolism in the same manner, their safety profile is meaningfully different. Real-world studies led by researchers at Johns Hopkins Bloomberg School of Public Health continue to track these long-term safety endpoints.
When to Consult a Doctor
References
- Pasqua, et al. (2025). Randomized Crossover Trial of Weekly Semaglutide in Type 1 Diabetes. Nature Medicine.
- Shah, et al. (2025). Clinical Evaluation of Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evidence.
- ADJUNCT ONE and ADJUNCT TWO Study Groups.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
